When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Keloid

Última revisión: 23 Aug 2025
Última actualización: 08 Oct 2024

Resumen

Definição

História e exame físico

Principais fatores diagnósticos

  • history of inciting event (e.g., body piercing, surgery, vaccination)
  • slow growth/lack of spontaneous regression
  • erythematous, smooth, and shiny elevated scar with overhanging edge
Detalhes completos

Outros fatores diagnósticos

  • itch or pain
Detalhes completos

Fatores de risco

  • history of prior keloid
  • local skin tension
  • follicular inflammation/infection
  • family history of keloid and genetic factors
  • dark skin types
  • hormonal status
  • systemic conditions (e.g., hypertension, atopic eczema, Castleman disease)
  • lifestyle factors
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • clinical diagnosis
Detalhes completos

Investigações a serem consideradas

  • skin biopsy
Detalhes completos

Algoritmo de tratamento

AGUDA

small/single keloid

large/bulky/multiple keloids

Colaboradores

Autores

Ioannis Goutos, FRCSEd(Plast)

Consultant Plastic Surgeon

Director of Academic Plastic Surgery Programmes

Queen Mary University of London

London

UK

Declarações

IG is an author of a number of references cited in this topic.

Richard Shaffer, MRCP, FRCR

Consultant Clinical Oncologist

GenesisCare

Cromwell Hospital

London

UK

Declarações

RS wrote the radiotherapy section of this topic. At the time of writing, he had received funds as a consultant as clinical lead for GenesisCare for skin and benign radiotherapy and as medical director for XStrahl, which designs and manufactures radiotherapy machines that can be used to treat keloid scars. RS has spoken at educational events on radiotherapy for keloid scarring and other benign and malignant conditions and has a working relationship with plastic surgeons who refer patients for radiotherapy for keloid scarring.Since contributing to the topic, RS has declared that he treats patients with radiotherapy for keloid scars in the private sector for GenesisCare and has received consulting fees from GenesisCare. He is also reimbursed for being a medical director and a shareholder and board member of Xstrahl Limited. He is board member and president of International Organisation for Radiotherapy for Benign Conditions (a community interest company), and has given webinars on the topic of radiotherapy for keloid scars for them. He is director and chief medical officer of Theralife, a company formed to treat patients with radiotherapy for non-cancer conditions. He works clinically with Ioannis Goutos for the benefit of patients with keloid scars. RS will not make further contributions to this topic.

Agradecimentos

Mr Ioannis Goutos and Dr Richard Shaffer would like to gratefully acknowledge Professor Andrew Burd, and Dr Lin Huang, previous contributors to this topic.

Declarações

AB and LH are authors of a number of references cited in this topic.

Revisores

Edward E. Tredget, MD, MSc, FRCSC

Director

Firefighters' Burn Treatment Unit and Plastic Surgery Wound Healing Research Laboratory

Professor

Department of Surgery

University of Alberta

Edmonton

Alberta

Canada

Declarações

EET declares that he has no competing interests.

Boni E. Elewski, MD

Professor and Chair of Dermatology

University of Alabama

Birmingham

AL

Declarações

BEE declares that she has no competing interests for this topic.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids: a 2020 update of the algorithms published 10 years ago. Plast Reconstr Surg. 2022 Jan 1;149(1):79e-94e.Texto completo  Resumo

Ogawa R, Akita S, Akaishi S, et al. Diagnosis and treatment of keloids and hypertrophic scars - Japan Scar Workshop consensus document 2018. Burns Trauma. 2019;7:39. Resumo

Gold MH, Berman B, Clementoni MT, et al. Updated international clinical recommendations on scar management: part 1 - evaluating the evidence. Dermatol Surg. 2014 Aug;40(8):817-24. Resumo

Royal College of Radiologists. Recommendations for using radiotherapy for benign disease in the UK. 2023 [internet publication].Texto completo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Keloid images
  • Diagnósticos diferenciais

    • Hypertrophic scar
    • Dermatofibrosarcoma protuberans
    • Dermatofibroma
    Mais Diagnósticos diferenciais
  • Diretrizes

    • Recommendations for using radiotherapy for benign disease in the UK: keloid scarring
    • S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids)
    Mais Diretrizes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal